AMPH — Amphastar Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $1.15bn
- $1.53bn
- $731.97m
- 91
- 90
- 45
- 89
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 7.32 | ||
| PEG Ratio (f) | 1.08 | ||
| EPS Growth (f) | 7.24% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.57 | ||
| Price to Tang. Book | 8.11 | ||
| Price to Free Cashflow | 6.67 | ||
| Price to Sales | 1.57 | ||
| EV to EBITDA | 5.82 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 14.63% | ||
| Return on Equity | 23.26% | ||
| Operating Margin | 28.06% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 349.85 | 437.77 | 498.99 | 644.39 | 731.97 | 734.26 | 782.76 | 17.82% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +75.25 | +46.98 | +14.22 | +1.88 | +18.51 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
Directors
- Mary Luo CHM (71)
- Jack Zhang PRE (74)
- William Peters CFO (53)
- Jacob Liawatidewi EVP (47)
- Rong Zhou EVP (62)
- Richard Prins LED (64)
- Diane Gerst DRC (61)
- Howard Lee IND (57)
- Floyd Petersen IND (77)
- Michael Zasloff IND (75)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 19th, 2004
- Public Since
- June 25th, 2014
- No. of Shareholders
- 116
- No. of Employees
- 2,028
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 47,502,192
- Address
- 11570 6th St, RANCHO CUCAMONGA, 91730
- Web
- https://amphastar.com/
- Phone
- +1 9099809484
- Auditors
- Ernst & Young LLP
Upcoming Events for AMPH
Amphastar Pharmaceuticals Inc Annual Shareholders Meeting
Amphastar Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Amphastar Pharmaceuticals Inc Earnings Release
Similar to AMPH
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
Arcutis Biotherapeutics
NASDAQ Global Select Market
FAQ
What is the Amphastar Pharmaceuticals share price?
As of Today at 19:13 UTC, shares in Amphastar Pharmaceuticals are trading at $24.19. This share price information is delayed by 15 minutes.
How has the Amphastar Pharmaceuticals share price performed this year?
Shares in Amphastar Pharmaceuticals last closed at $24.19 and the price had moved by -40.75% over the past 365 days. In terms of relative price strength the Amphastar Pharmaceuticals share price has underperformed the S&P500 Index by -45.31% over the past year.
What are the analyst and broker recommendations for Amphastar Pharmaceuticals?
The overall consensus recommendation for Amphastar Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Amphastar Pharmaceuticals dividend yield?
Amphastar Pharmaceuticals does not currently pay a dividend.
Does Amphastar Pharmaceuticals pay a dividend?
Amphastar Pharmaceuticals does not currently pay a dividend.
When does Amphastar Pharmaceuticals next pay dividends?
Amphastar Pharmaceuticals does not currently pay a dividend.
How do I buy Amphastar Pharmaceuticals shares?
To buy shares in Amphastar Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Amphastar Pharmaceuticals?
As of the previous close price of $24.19, shares in Amphastar Pharmaceuticals had a market capitalisation of $1.15bn.
Where are Amphastar Pharmaceuticals shares listed?
Here are the trading details for Amphastar Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: AMPH
What kind of share is Amphastar Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Amphastar Pharmaceuticals is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Amphastar Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Amphastar Pharmaceuticals is $35.25. That is 45.72% above the last closing price of $24.19.
Analysts covering Amphastar Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $3.12 for the next financial year.
Find out moreWhat is the trend in the Amphastar Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Amphastar Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -49.3%.
As of the last closing price of $24.19, shares in Amphastar Pharmaceuticals were trading -38.52% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Amphastar Pharmaceuticals PE Ratio?
The Amphastar Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 7.32. The shares last closed at $24.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals' management team is headed by:
- Mary Luo - CHM
- Jack Zhang - PRE
- William Peters - CFO
- Jacob Liawatidewi - EVP
- Rong Zhou - EVP
- Richard Prins - LED
- Diane Gerst - DRC
- Howard Lee - IND
- Floyd Petersen - IND
- Michael Zasloff - IND